Compare Ascendis Pharma A/S (ASND) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Redwire Corporation — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Redwire Corporation trades at $13.67 (market cap $3.28B). The key difference: Ascendis Pharma A/S is far larger — about 5.1× Redwire Corporation's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| ASND | RDW | |
|---|---|---|
Market Cap | $16.78B | $3.28B |
Sector | Health | Technology |
52-Week High | $277.18 | $25.90 |
52-Week Low | $189.74 | $5.06 |
Enterprise Value | $17.15B | $2.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
RDW stock trades at $13.59, up 14.88% in the last 24 hours, reflecting strong momentum after Q2 2026 results. The company reported record revenue of $117.1 million and a growing backlog of $542.1 million, though it remains unprofitable with a net income margin of -57.26%. Technical indicators show a bullish trend, with the current price near the consensus target of $17.50, while analyst sentiment is overwhelmingly positive with 80% buy ratings.
The outlook hinges on execution of its space and defense contracts, but persistent losses and negative cash flows from operations pose significant risks. Upside potential exists if margin improvements materialize, yet investors face volatility from earnings misses and high burn rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
